Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At least he stoked the fire of Ariad over $10 per share..
He just showed the world the quality of the research and the reporting at The Street dot com..
Well, UNG has absolutely collapsed, and there is no support in sight.. Could we see $3 for this NG EFT??
This should be the beginning of the 6%-15% correction in the markets that should be expected..
In the end, Harvey delievers (even though the majority here disagrees).. He has accomplished EVERYTHING that he said he would.
I would expect that the interm analysis of Pona before the end of THIS year, will support and/or cover up what Rida delievers..
BTR
I'm sorry vidpok45, how did I violate the TOS from post #5848?? Please explain...
Manic-Depressive..
Don't drink the negative poster's Kool Aid.....
This too shall pass..
I just need Ariad to rock and roll before the long term cap gain of 15% is a distant memory as well... I absolutely expect that we will accomplish that.. In the spirit of who provided that benefit to us, dare I say, "mission accomplished"???
Harvey also STRONGLY indicated that they will have an interm look/analysis on Pona. Since they started the trial in the fall, you would expect that we will have a look before the end of the year. Then, let the bidding begin!
Comments from call:
Data on Rida results to be presented mid year (not that far away) at a conference.
Ariad confirmed that Merck will file Rida this year.
Merck to initiate additional trials with Rida in single agent and combinational trials.
Merck to initiate a phase 3 trial with Rida in Endo cancer
Merck to initiate further trials in combo with their IGFR drug in her2 breast cancer.
Merck has halted Rida in prostate cancer and lung cancer.
Ariad is looking beyond CML for pona (AML, multi meloma, and otheres)
All three of their compounds will have papers presented on other indications for their use..
Co promotion of Rida with Merck means Ariad salesforce would promote Rida.. Harvey waffled on that so I think that is a non starter (I hope).
Look again, BTH..
Damn, they sure can burn through the cash..
Remarkably, here is a chart of a stock that some call a "pig"!
http://finance.yahoo.com/q/bc?s=ARIA&t=1y&l=on&z=l&q=l&c=
From what all my investment reference information, and contacts tell me, this is a classic IBD basing pattern, and with a biotech stock like this, it doesn't last too much longer.. It will resolve itself very soon...
What is sad is that Ariad should be trading at this price on JUST the Endo results..
Oh, it's a scam all right.. Read the choice of compounds on their web site.. You may find some that fit your fancy..
I've seen those ads before, where you can buy unapproved compounds by the pound. I believe it is a scam..
In fact, I promise you that a partnership deal struck at the end of this year for Pona, will be worth a lot more than one struck today.. They should not be in any rush to sign the deal.
One new piece of information from Harvey is that Ariad plans to launch Pona in select E.U. countries, and partner in the rest of the E.U... France, U.K., Germany, and ?
I think the most we can expect is that Ponatinib enrollment is ahead of schedule....and Merck will begin Endo phase 3.. That would be a home run..
DewDiligence, I agree.. 2da, just let Harvey run the business..if you can hold on, you will be rewarded..
What it is incredible is MNKD, which has nothing, STILL has a market cap of $500 million, and here Ariad sits, with a robust pipline, has only a market cap of $800 million. I expect both market caps are currently not correct and will diverge soon..
I like it... Rida gets front billing in Ariad's PR this morning:
ARIAD's vision is to transform the lives of cancer patients with breakthrough
medicines. The Company's mission is to discover, develop and commercialize
small-molecule drugs to treat cancer in patients with the greatest and most
urgent unmet medical need -- aggressive cancers where current therapies are
inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational
mTOR inhibitor being developed by Merck that has successfully completed a Phase
3 clinical trial in patients with soft-tissue and bone sarcomas and is being
studied in multiple cancer indications. ARIAD's second internally discovered
product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a
pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+
acute lymphoblastic leukemia.
What matters is you create compounds that work to inhibit the growth of cancers, especially cancers that have generated mutant complexities, obtain FDA approval on those compounds, and yes then, obtain patents on those drugs for x number of years.. That's the best way of creating sharholder value, and helping a whole lot of patients..
Patent on a process has not been one of Ariad's strong suits..
"The inhibitory mechanism exemplified by ponatinib may have broad relevance to designing inhibitors against other kinases with mutated gatekeeper residues."
Simply.. WOW!!
You know, if Mr. Market could connect the dots, Ariad would be at $10 per share.. Take this article on PFE's ALK drug. This is the same target that Ariad is going after with their '113. Difference is Ariad's drug is 10X more potent... Inefficient market theory??.. They just don't get it...
http://pharmastrategyblog.com/2011/02/molecular-subsets-in-lung-cancer.html/
No bounce today............
It's the time of the day that we usually bounce, and rise into the close.. It has been remarkablely repeatable..
Dew, I'm just spreading some cheer.. The discounted true value of Ariad out three years is an unknown at this time..
lax, here is another biotech, same pattern as DNDN, that in reality, will not fill the gap.. Honestly, I find some that use TA follow it way, way too closely..
http://finance.yahoo.com/q/bc?s=INCY+Basic+Chart&t=5y
Even with Merck's depressed stock price, I still would accept a one-for-one stock buyout..
lax20m, the period of 2007 to 2009 was a once-in-a-generation period for the market..
And, a spot on follow up post from Biomaven:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59530780
Priced at $34 today, $23 million in trailing revenue, $5 Billion market cap, never filled any 'ole gap:
http://finance.yahoo.com/q/bc?s=DNDN&t=5y&l=on&z=l&q=l&c=
Now, we just need someone to call into the Merck CC this morninig and ask "with such good results in the Endo trial with Rida that you stopped the trial early, what are your development plans for that indication"?? BTH, what say you??